Kymera Therapeutics, Inc.
KYMR
Kedudukan dalam Saham
#2177
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Harga Saham
$114.06
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$9.38B
Perubahan (1 hari)
5.54%
Perubahan (1 tahun)
95.57%
Negara
US
Perdagangan Kymera Therapeutics, Inc. (KYMR)
Kategori
Healthcare
Hasil untuk Kymera Therapeutics, Inc. (KYMR)
Hasil pada Jun 2026 TTM: $104.99M
Menurut laporan kewangan terkini daripada Kymera Therapeutics, Inc., hasil semasa syarikat (TTM) ialah $104.99M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $78.59M peningkatan berbanding hasil pada tahun 2022 iaitu $46.83M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Kymera Therapeutics, Inc. dari 2018 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $104.99M | 123.04% |
| 2024 | $47.07M | -40.11% |
| 2023 | $78.59M | 67.84% |
| 2022 | $46.83M | -35.71% |
| 2021 | $72.83M | 114.00% |
| 2020 | $34.03M | 1,059.99% |
| 2019 | $2.93M | 0.00% |
| 2018 | 0.00 | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 11,924.40% |
US
|
|
| $2.23B | 2,022.13% |
US
|
|
| $15.74B | 14,896.17% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 5,635.16% |
NL
|
